货号 | 7246S |
反应种属 | Human/Mouse |
应用 | ELISA |
目标/特异性 | For Antibody Pair specificity and sensitivity, please refer to the corresponding PathScan® Sandwich ELISA Kit. Note: This antibody pair detects proteins from the indicated species, as determined through in-house testing, but may also detect homologous proteins from other species. |
供应商 | CST |
背景 | Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines (1-3) and is an important target in the diagnosis and treatment of cancer (4). Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family as well as Mos and Tpl2/Cot. MEK1 and MEK2 are the primary MAPKKs in this pathway (5,6). MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK (7) and the transcription factor Elk-1 (8,9). p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs (10), along with MEK inhibitors such as U0126 and PD98059. |
存放说明 | 4C |
参考文献 | Roux, P.P. and Blenis, J. (2004) Microbiol Mol Biol Rev 68, 320-44. Baccarini, M. (2005) FEBS Lett 579, 3271-7. Meloche, S. and Pouysségur, J. (2007) Oncogene 26, 3227-39. Roberts, P.J. and Der, C.J. (2007) Oncogene 26, 3291-310. Rubinfeld, H. and Seger, R. (2005) Mol Biotechnol 31, 151-74. Murphy, L.O. and Blenis, J. (2006) Trends Biochem Sci 31, 268-75. Dalby, K.N. et al. (1998) J Biol Chem 273, 1496-505. Marais, R. et al. (1993) Cell 73, 381-93. Kortenjann, M. et al. (1994) Mol Cell Biol 14, 4815-24. Owens, D.M. and Keyse, S.M. (2007) Oncogene 26, 3203-13. |
The relationship between the protein concentration of the lysate from untreated and PDGF-treated NIH/3T3 cells and the absorbance at 450 nm using PathScan® Phospho-p44/42 MAPK (Thr202/Tyr204) Sandwich ELISA Antibody Pair #7246 is shown. NIH/3T3 cells were treated with PDGF (100 ng/mL) for 5 minutes at 37ºC and then lysed.图中显示了未经处理和PDGF处理的NIH/3T3细胞溶解产物蛋白质浓度与450 nm 处光学密度读数之间的关系,使用的抗体是PathScan® Phospho-p44/42 MAPK (Thr202/Tyr204) Sandwich ELISA Antibody Pair #7246。NIH/3T3细胞用PDGF (100 ng/mL) 处理,37ºC 处理5min后裂解。 |